BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 36847231)

  • 41. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In-vitro Anti-cancer assay and apoptotic cell pathway of newly synthesized benzoxazole-N-heterocyclic hybrids as potent tyrosine kinase inhibitors.
    Desai S; Desai V; Shingade S
    Bioorg Chem; 2020 Jan; 94():103382. PubMed ID: 31662214
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New Approaches for the Synthesis of Heterocyclic Compounds Corporating Benzo[d]imidazole as Anticancer Agents, Tyrosine, Pim-1 Kinases Inhibitions and their PAINS Evaluations.
    Mohareb RM; Milad YR; Mostafa BM; El-Ansary RA
    Anticancer Agents Med Chem; 2021; 21(3):327-342. PubMed ID: 32698742
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quinazolin-4(3
    Mirgany TO; Abdalla AN; Arifuzzaman M; Motiur Rahman AFM; Al-Salem HS
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2055-2067. PubMed ID: 34551654
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
    Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
    Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Heterocyclization of 2-(2-phenylhydrazono)cyclohexane-1,3-dione to Synthesis Thiophene, Pyrazole and 1,2,4-triazine Derivatives with Anti-Tumor and Tyrosine Kinase Inhibitions.
    Mohareb RM; Alwan ES
    Anticancer Agents Med Chem; 2020; 20(10):1209-1220. PubMed ID: 32156245
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations.
    Aziz NAAM; George RF; El-Adl K; Mahmoud WR
    Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200465. PubMed ID: 36403198
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Design, Synthesis and Antitumor Activities of Novel Quinazolinone Derivatives as Potential EGFR Inhibitors.
    Wang J; Huang L; Chen X; Yuan Y; Sun J; Yang M
    Chem Pharm Bull (Tokyo); 2022; 70(9):637-641. PubMed ID: 36047235
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rational design-aided discovery of novel 1,2,4-oxadiazole derivatives as potential EGFR inhibitors.
    Unadkat V; Rohit S; Parikh P; Sanna V; Singh S
    Bioorg Chem; 2021 Sep; 114():105124. PubMed ID: 34328857
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design, synthesis and docking studies of benzimidazole derivatives as potential EGFR inhibitors.
    Celik İ; Ayhan-Kılcıgil G; Guven B; Kara Z; Gurkan-Alp AS; Karayel A; Onay-Besikci A
    Eur J Med Chem; 2019 Jul; 173():240-249. PubMed ID: 31009910
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
    Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
    El-Sayed NA; Nour MS; Salem MA; Arafa RK
    Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In Silico and In Vitro Evaluations of Fluorophoric Thiazolo-[2,3-b]quinazolinones as Anti-cancer Agents Targeting EGFR-TKD.
    Mir SA; Dash GC; Meher RK; Mohanta PP; Chopdar KS; Mohapatra PK; Baitharu I; Behera AK; Raval MK; Nayak B
    Appl Biochem Biotechnol; 2022 Oct; 194(10):4292-4318. PubMed ID: 35366187
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis of stable benzimidazole derivatives bearing pyrazole as anticancer and EGFR receptor inhibitors.
    Akhtar MJ; Khan AA; Ali Z; Dewangan RP; Rafi M; Hassan MQ; Akhtar MS; Siddiqui AA; Partap S; Pasha S; Yar MS
    Bioorg Chem; 2018 Aug; 78():158-169. PubMed ID: 29571113
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of pyridazine derivatives as potential EGFR inhibitors and apoptosis inducers: Design, synthesis, anticancer evaluation, and molecular modeling studies.
    Ahmed MF; Santali EY; Mohi El-Deen EM; Naguib IA; El-Haggar R
    Bioorg Chem; 2021 Jan; 106():104473. PubMed ID: 33243490
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New pyrimidine and pyrazole-based compounds as potential EGFR inhibitors: Synthesis, anticancer, antimicrobial evaluation and computational studies.
    Othman IMM; Alamshany ZM; Tashkandi NY; Gad-Elkareem MAM; Anwar MM; Nossier ES
    Bioorg Chem; 2021 Sep; 114():105078. PubMed ID: 34161878
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis, antitumour activities and molecular docking of thiocarboxylic acid ester-based NSAID scaffolds: COX-2 inhibition and mechanistic studies.
    El-Azab AS; Abdel-Aziz AA; Abou-Zeid LA; El-Husseiny WM; El Morsy AM; El-Gendy MA; El-Sayed MA
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):989-998. PubMed ID: 29806488
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 1,2,3-triazole tethered Indole-3-glyoxamide derivatives as multiple inhibitors of 5-LOX, COX-2 & tubulin: Their anti-proliferative & anti-inflammatory activity.
    Naaz F; Preeti Pallavi MC; Shafi S; Mulakayala N; Shahar Yar M; Sampath Kumar HM
    Bioorg Chem; 2018 Dec; 81():1-20. PubMed ID: 30081353
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
    Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
    Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.